{"id":"W3196898846","doi":"10.1016/s2152-2650(21)01833-4","title":"MPN-332: Clinical Benefit of Pelabresib (Cpi-0610) in Combination with Ruxolitinib in JAK Inhibitor Treatment-Naïve Myelofibrosis Patients: Interim Efficacy Subgroup Analysis from Arm 3 of the MANIFEST Phase 2 Study","year":2021,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Ruxolitinib; Medicine; Context (archaeology); Myelofibrosis; Internal medicine; Clinical endpoint; Gastroenterology; Phases of clinical research; Clinical trial; Bone marrow; Biology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003209362,0.001879443,0.003840921,0.0006152719,0.0003203899,0.001576634,0.0008221674,0.001003137,0.003098512],"category_scores_gemma":[0.001722425,0.0007158738,0.006268958,0.0006399369,0.0006144951,0.001100588,0.0005949337,0.002916913,0.0005474936],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008646214,"about_ca_system_score_gemma":0.0009893361,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000837106,"about_ca_topic_score_gemma":0.003709302,"domain_scores_codex":[0.9988379,0.0006322826,0.00008038127,0.000188141,0.000101113,0.0001602521],"domain_scores_gemma":[0.9992533,0.0002235909,0.0002134755,0.0001199781,0.00004027104,0.0001493641],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.9325876,0.001672366,0.008737436,0.000794079,0.01630292,0.00009055358,0.00006124451,0.001859829,0.005191777,0.0001411135,0.002014992,0.03054608],"study_design_scores_gemma":[0.7872016,0.08148786,0.08212551,0.0002226964,0.03720057,0.0003296114,0.0001478544,0.003996723,0.002316096,0.001045122,0.003768618,0.0001578047],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9840537,0.009520222,0.0006839348,0.0005648395,0.0002091662,0.0006624304,0.002609506,0.0001161743,0.001580037],"genre_scores_gemma":[0.9910993,0.002172705,0.0007086569,0.0006166825,0.0002365611,0.0005702533,0.003252011,0.00003410268,0.00130974],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003840921,"threshold_uncertainty_score":0.01697296,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.04502401486873477,"score_gpt":0.3788864568032972,"score_spread":0.3338624419345625,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}